PGTx is a biologics company developing vaccines and an adjuvant delivery system for pressing unmet global human health needs. Our mission is to apply scientific innovation to provide global access to affordable vaccines and to be a profitable enterprise.
The company’s novel technology enables the development of a vaccine providing broad cross-protection among related pathogens. The PGTx dysenteric vaccine, vectored in both live attenuated and inactivated bacteria, is a potential game changer in vaccinology. It addresses neglected tropical and emerging infectious diseases causing major global health problems, but where there are no successful vaccines and/or therapies.
PGTx’s dysenteric vaccine leverages ten years and millions of dollars of successful research and development in veterinary and pre-clinical animal studies. These were carried out at research institutions across the globe, and the vaccines have demonstrated safety and efficacy in multiple animal models.
PGTx’s Hercules adjuvant delivery system safely delivers vaccines mucosally via the oral and intranasal routes. Hercules revolutionizes vaccine delivery and distribution with an oral vaccine that can be easily deployed in low-income countries.
PGTx’s goals support the U.N. Sustainable Development Goals and embrace the One Health concept where human and animal wellbeing are interdependent.